People's republic of china *These authors contributed equally to this work Background: Despite advances in clinical therapies and technologies, the prognosis for patients with gastric cancer is still poor. The aim of this study is to investigate new predictive markers for prognosis of gastric cancer. Methods: In this study, we evaluated the expression pattern of PIK3CA in 107 gastric cancer specimens and their adjacent nontumorous tissues. PIK3CA siRNA was synthesized and transfected into gastric cancer cell lines. Colony formation and MTT assays were employed to analyze the cell proliferation. PIK3CA expression was examined by using immunohistochemical analysis and Western blot assay. Transwell invasion assay was used to detect the invasion capability of the cells. Luciferase activity was examined by using 3′-untranslated region luciferase reporter assays. Results: We observed that PIK3CA was significantly upregulated in gastric cancer tissues. High expression level of PIK3CA was detectable in 48 (44.86%) of the gastric cancer specimens, and correlated with poor prognosis. In addition, our study indicated that miR203 inhibits cell proliferation and invasion via directly targeting and suppressing the PIK3CA expression. MiR203 expression is downregulated in gastric cancer tissues. Moreover, low expression level of miR203 predicted poor prognosis of gastric patients and induced overexpression of PIK3CA. Our further study also reported that overexpression of miR203 inhibited phosphorylation of AKT, while cotransfection of PIK3CA reversed the effect of miR203. Conclusion: Our study suggested a miR203-PIK3CA-AKT signaling pathway in gastric cancer cells. This signaling pathway might play an important role in gastric cancer genesis and development.
Introduction
Gastric cancer is the second leading cause of cancer-related deaths worldwide. The incidence of gastric cancer is comparatively higher in the Eastern Asia, and 65%-70% of new cases of deaths are reported from gastric cancer in less-developed countries. 1 In 2009, the incidence rate of gastric cancer ranked third among the most common cancers in People's Republic of China. 2 Currently, surgery is one of the most common treatments of gastric cancer but survival rate of patients is less than 33%. 3, 4 Thus, there is an immense need to identify novel and promising therapeutic target for the cure and treatment of gastric cancer. Previous studies have revealed several genes related to human gastric cancer, but successful therapeutic targets are limited. Thus, the molecular mechanisms of gastric cancer are of great importance and remain to be elucidated.
PIK3CA gene is located at 3q26.3 and encodes the key enzymatic subunit p110α of phosphatidylinositol 3-kinase (PI3K). 5 important role in carcinogenesis. 6 PIK3CA functions as an oncogene, which plays important roles in many cancers, including gastric cancer [7] [8] [9] and colorectal cancer. [10] [11] [12] Our previous studies have demonstrated that overexpression of PIK3CA increased invasion and proliferation of gastric cancer cells. 13 Moreover, the increased expression level of PIK3CA in gastric cancer tissues is associated with lymph node metastasis. 13, 14 On this basis, we investigate the upstream and downstream molecules of PIK3CA and identify that PIK3CA is a novel target of miR203 in gastric cancer. A decrease in miR203 expression upregulates PIK3CA, and thus activates PI3K/AKT signaling pathway and increases invasion and proliferation of gastric cancer cells. Moreover, we also demonstrate that low expression level of miR203 correlates with high expression level of PIK3CA, and both decreased miR203 expression and increased PIK3CA expression correlate with poor prognosis of gastric cancer patients.
Materials and methods

Patients and specimens
The study was approved by the Institutional Review Board and Human Ethics Committee of Affiliated Oncologic Hospital of Guangzhou Medical University. Written consent for using the samples for research purposes was obtained from all patients prior to surgery. We collected tissue from 107 patients with advanced gastric carcinoma who were treated at the Affiliated Oncologic Hospital of Guangzhou Medical University (Guangzhou, People's Republic of China) between June 2005 and December 2008. All the patients were monitored after surgery until September 31, 2012. A total of 107 gastric carcinoma samples (tumor and matched adjacent nontumorous tissues) were used in the immunohistochemistry (IHC) analysis.
cell lines, transfection, and antibodies
The gastric cancer cell lines SGC-7901, BGC-823, MGC-803, and HGC-27 were cultured in RPMI 1640 (Thermo Scientific, Waltham, MA, USA) medium supplemented with 10% fetal bovine serum, 50 mg/mL streptomycin, and 50 U/mL penicillin in a humidified atmosphere containing 5% CO 2 at 37°C. All antibodies used in this study were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). MiR203 mimics and miR203 antisense oligonucleotides (ASO) were purchased from Shanghai GenePharma (Shanghai, People's Republic of China). Transfections were carried out using Lipofectamine-2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions.
immunohistochemical analysis
Formalin-fixed, paraffin-embedded tissue specimens from gastric carcinoma patients were cut in 5 µm sections. Briefly, after deparaffinized in xylene and rehydrated, the tissue slides were then treated with 3% hydrogen peroxide, and the antigens were retrieved in sodium citrate buffer (pH 6.0) using a microwave oven. After 1 hour of preincubation in goat serum to prevent nonspecific staining, the specimens were incubated with primary antibodies overnight at 4°C. The tissue slides were treated with a non-biotin horseradish peroxidase detection system according to the manufacturer's instructions (DAKO, Glostrup, Denmark). Two different pathologists evaluated the results of IHC. Both the extent and intensity of immunostaining were taken into consideration. The intensity of staining was scored from 0 to 3, and the extent of staining was scored from 0% to 100%. The final score of each staining was obtained by multiplying the two scores. The pAKT expression was recognized as higher level, if the score was higher than 1.5; if the score was 1.5 or less, the case was classified as low expression. PIK3CA expression was considered high if the score reached 0.5.
colony formation and MTT assays
SGC-7901 and HGC-27 cells in the logarithmic growth phase were planted into six-well plate with 200 cells per well. The cells were continuously cultured for 9 days. The RPMI-1640 medium was then discarded. The cells were washed with phosphate buffered saline (PBS; pH 6-8) twice, fixed with methyl alcohol for 20 minutes, stained with 10% Giemsa stain for 20 minutes, washed with distilled water, and then dried. Colonies containing more than 50 cells were counted. For MTT assay, 1,000 cells were seeded into a 96-well plate and cultured for 24, 48, and 72 hours. The MTT was then added (concentration of 5 mg/mL, 10 µL/well). The cells were then cultured for 4 hours and centrifuged at 1,000 rpm for 5 minutes. The supernatant liquid was discarded. About 150 µL of DMSO was added per well, followed by agitating for 10 minutes to completely dissolve the crystals. A wavelength of 570 nm was selected, and the optical density per well was detected.
Transwell invasion assay
Transwell invasion assay was performed using the BD BioCoat Matrigel Invasion Chamber (BD Bioscience, San Jose, CA, USA). Briefly, 2×10 4 cells were placed into the top chamber of each insert and incubated at 37°C for 48 hours. Cells that invaded through the Matrigel were stained using crystal violet (Sigma-Aldrich Co., St Louis, MO, USA) and quantified.
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Mir203 negatively regulates PIK3CA rna extraction and real-time Pcr
Reverse transcription polymerase chain reaction (RT-PCR) was performed using TaqMan ® MicroRNA Reverse Transcription Kit and TaqMan ® Universal PCR Master Mix (Ambion, Austin, TX, USA). For analysis of miR203 expression (U6 small nuclear RNA, a reference gene), we employed a two-step quantitative reverse transcription PCR (qRT-PCR) with specific primers for miR203 (we used the subclassification of miR-203-3p) (Applied Biosystems, Foster City, CA, USA) following the manufacturer's protocol. Real-time RT-PCR was performed using a PRISM 7300 Sequence Detection System (Applied Biosystems), in which each reaction (25 µL) contained 10 µL PCR Master Mix (Ambion) and 1.33 µL RT product, and each sample was analyzed in triplicates. PCR was carried out at 95°C for 10 minutes, followed by 40 cycles of amplification at 95°C for 15 seconds and 60°C for 60 seconds. Results are representative of two independent assays. Relative fold changes of expression in tumor tissues were calculated using the comparative Ct (2 -∆∆Ct ) method with U6 small nuclear RNA (Ambion) as the endogenous control.
sirna synthesis and transfection
The siRNAs were designed and synthesized by GenePharma. PIK3CA siRNA: sense 5′-GGC UAA AGA AAG CCU UUA UTT-3′, antisense 5′-AUA AAG GCU UUC UUU AGC CTT-3′; negative control siRNA: sense 5′-UUC UCC GAA CGU GUC ACG UTT-3′, antisense 5′-ACG UGA CAC GUU CGG AGA ATT-3′. All sequences were submitted to National Institutes of Health Blast program to ensure gene specificity.
Vector construct
The pcDNA-PIK3CA was used as a template. PCR amplification was performed by using a standard protocol with the primers: sense 5′-GGC UAA AGA AAG CCU UUA UTT-3′, antisense 5′-AUA AAG GCU UUC UUU AGC CTT-3′; Negative control siRNA: sense 5′-UUC UCC GAA CGU GUC ACG UTT-3′, antisense 5′-ACG UGA CAC GUU CGG AGA ATT-3′. The gene was purified and inserted into pcDNA3.1 vector. The recombinant plasmid (pcDNA-PIK3CA) was confirmed by sequencing.
3′-UTr luciferase reporter assays
Firefly luciferase reporter plasmids, pMIR-REPORT (Ambion) containing 3′-untranslated region (UTR) and 3′-UTR-mut of the PIK3CA gene or empty luciferase vector obtained from Ambion were used for luciferase reporter assay. Cells were seeded in a 48-well plate and were cotransfected with miR203 mimics, ASO as well as PIK3CA-3′UTR or PIK3CA-3′UTR-mut. Luciferase activity was analyzed 24 hours post-transfection using the Luciferase Reporter Assay System (Promega, Madison, WI, USA) following the manufacturer's instructions.
Western blot
The specimens were snap-frozen in liquid nitrogen and immediately homogenized in ice-cold RIPA lysis buffer (Sigma-Aldrich Co.). Denatured total tissue lysates were run in sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), transferred to nitrocellulose membranes, and blocked overnight at 4°C in 5% milk. The blocked membranes were incubated overnight at 4°C with the PIK3CA monoclonal antibody (Santa Cruz, 1:4,000), pAKT monoclonal antibody (Santa Cruz, 1:3,000), the AKT monoclonal antibody (Santa Cruz,1:3000), and β-actin monoclonal antibody (Santa Cruz, 1:2,000) followed by 1 hour incubation at room temperature with an HRP (horseradish peroxidase)-conjugated secondary antibody (Santa Cruz, 1: 1,000). Immunodetection was performed using the ECL+ reagents (Amersham Biosciences, Buckinghamshire, UK). Signals were normalized against β-actin and the results were expressed as a percentage of the negative control signal.
statistics
All statistical analyses were performed with SPSS statistical software (version 21.0; SPSS, IBM, Armonk, NY, USA). Survival curves were constructed using the Kaplan-Meier method and analyzed by the log-rank test. The two-tailed chi-squared test was used to compare count data. The Student's t-test was used for comparisons. P-values ,0.05 were considered to be statistically significant.
Results
Overexpression of PIK3CA indicates poor prognosis of gastric patients
In our previous study, 8 we have demonstrated that PIK3CA could increase proliferation and invasion of gastric cancer cells. Hence, we detected expression level of PIK3CA in gastric cancer and adjacent nontumorous tissues. By using IHC assays, we detected high expression of PIK3CA in 48/107 gastric cancer tissues, compared with only 22/107 in adjacent nontumorous tissues (P,0.001; Figure 1A 
PIK3CA is a novel target of mir203
Overexpression of PIK3CA indicated poor prognosis of gastric cancer patients; however, the mechanism of aberrant PIK3CA expression in gastric cancer is still unclear. By performing bioinformatics analysis, we supposed that PIK3CA is a potential target of miR203 (Figure 2A, up panel) . To verify this correlation, we performed luciferase assays and found that miR203 could inhibit luciferase activity of PIK3CA 3′UTR-Luc vector transfected group but not PIK3CA 3′UTR-mutated-Luc vector group (Figure 2A, down panel) . Then we tested expression levels of miR203 and PIK3CA in four gastric cancer cells. The results illustrated that there was a negative trend of PIK3CA expression in cells showing high expression of miR203 ( Figure 2B and C) . Moreover, the transfection of miR203 mimics and miR203 ASO indicated that miR203 mimics could decrease PIK3CA expression in PIK3CA high-expression gastric cell line, HGC-27. However, miR203 ASO could increase PIK3CA expression in SGC-7901, a miR203 high-expression but PIK3CA lowexpression cell line ( Figure 2D ).
Next, we analyzed the influence of miR203 on proliferation, colony formation, and invasion of gastric cancer cells. We found miR203 mimics could decrease proliferation, colony formation, and invasion of gastric cancer cells; however, miR203 ASO could increase proliferation, colony formation, and invasion of gastric cancer cells ( Figure 2F-I) . To further confirm the hypothesis that miR203 exerts anti-cancer effect due to inhibition of PIK3CA expression, we designed siRNA targeted to PIK3CA and constructed PIK3CA expression vector ( Figure 2E ). The cotransfection indicated that PIK3CA siRNA and expression vector reversed the effect of miR203 mimics and miR203 ASO ( Figure 2F-I) . These experiments demonstrated that miR203 targeted and inhibited PIK3CA expression. Moreover, miR203 exerted its anti-cancer effect via inhibition of PIK3CA expression.
PIK3CA expression is associated with mir203 and phosphorylation of aKT
To further confirm expression profile of miR203 in gastric cancer tissues, we performed real-time quantitative PCR in 107 cases of gastric cancer and adjacent nontumorous tissues. In general, an average three-to fourfold decrease for miR203 expression was noted in gastric cancer tissues as compared with that of adjacent nontumorous tissues ( Figure 3A) . Comparative analysis of paired gastric cancer tissues with adjacent nontumorous tissues further revealed that reduced miR203 expression (more than twofold) was observed in 85 (79.42%) cases, suggesting that reduction of miR203 was a frequent event in human gastric cancer. Furthermore, we found that miR203 expression level was negatively correlated with PIK3CA expression ( Figure 3B ). This result verified that miR203 targeted PIK3CA and inhibited PIK3CA expression. Next, analysis was conducted between two groups, one with high miR203 expressions, while the other with low miR203 expressions. It was found that patients with high miR203 expressions had much longer overall survival time and disease-free survival time than those with low miR203 expressions ( Figure 3C and D) .
It has been reported that PIK3CA promotes phosphorylation of AKT in many types of cancer.
14-16 Therefore, we detected the correlation between PIK3CA expression and AKT phosphorylation. IHC assays in serial sections of gastric cancer tissues indicated that overexpression of PIK3CA positively correlated with AKT phosphorylation (Figure 3E and F) . Furthermore, in vitro experiments also indicated that downregulation of PIK3CA was accompanied with decreased AKT phosphorylation and upregulation of PIK3CA was accompanied with increased AKT phosphorylation ( Figure 3G ). Interestingly, AKT phosphorylation is also a predictor for gastric cancer patients, and high expression of pAKT correlated with poor prognosis (Figure 3H and I).
Mir203 can suppress PIK3CA/aKT pathway
To investigate the function of miR203 on PIK3CA/AKT pathway in breast cancer cells lines, miR203 mimics were transfected into HGC27 cells. As shown in Figure 4A , miR203 mimics decreased expression of PIK3CA and pAKT. Furthermore, we observed that overexpression of PIK3CA can abrogate the effect of miR203 on the expression of PIK3CA and pAKT ( Figure 4A ). We then confirmed that miR203 decreased colony formation and invasion ability of cells and overexpression of PIK3CA abrogated the effect of miR203 ( Figure 4C and E) .
In addition, we observed that miR203 ASO increased the expression of PIK3CA and pAKT, and knockdown of PIK3CA abrogated miR203 ASO induced increase of pAKT ( Figure 4B ). Colony formation and invasion assays of the cells further confirmed that miR203 facilitated the colony formation and invasion abilities, and knockdown of PIK3CA by si-PIK3CA transfection rescued this process ( Figure 4D  and F) . Therefore, these results demonstrated that miR203 can suppress the PIK3CA/AKT pathway.
Discussion
Gastric cancer is the second largest cause of cancer deaths worldwide. 17 However, the underlying mechanisms involved in the development of gastric cancer have not been fully elucidated. Understanding the molecular mechanisms involved in the progression of gastric cancer will help in developing new diagnostic and therapeutic strategies. In recent years, many researchers have focused on signaling pathway deregulation in cancers. Among them, dysregulation of the PI3K/AKT pathway in a wide spectrum of human cancers has become a research hot spot.
13 PIK3CA, as an important component of PI3K, plays important role in PI3K/AKT signaling pathway. 18 In this study, we found that PIK3CA is aberrantly expressed in gastric tissue and the aberrant expression of PIK3CA predicted poor prognosis of gastric cancer patients. Through bioinformatics analysis and experiments, we identified miR203 as an upstream molecular of PIK3CA signaling pathway, which could inhibit PIK3CA expression. MiR203 is one kind of microRNAs (miRNAs), which is composed of 19-24 nucleotides and noncoding RNA. 19 In recent years, growing evidence has suggested that dysregulation of miRNAs contributes to tumor genesis. 20 Studies have shown that more than 50% of miRNAs are located in cancer-associated genomic regions or in fragile sites. 21 MiR203 was found to be significantly downregulated during malignant transformation in a wide variety of tumors. 22 In this study, we found miR203 expression level was downregulated in gastric cancer tissue, and thus induced overexpression of PIK3CA. The low expression of miR203 also predicted poor prognosis of gastric cancer. Moreover, we found miR203 exerted anti-cancer effect via inhibiting proliferation and invasion of gastric cancer cells. Further study suggested that the anti-cancer effect of miR203 is, at least partly, due to the inhibition of PIK3CA expression. On account of the correlation between PI3K and phosphorylation of AKT, we also detected phosphorylation level of AKT in gastric cancer tissues and cells that knocked down or overexpressed PIK3CA. Interestingly, we found that PIK3CA expression level positively correlated with phosphorylation of AKT. These results suggested that there is a miR203-PIK3CA-AKT signaling pathway in gastric cancer cells. MiR203 down-regulation induced overexpression of PIK3CA and thus promoting phosphorylation of AKT, the important effector downstream of PI3K. This pathway might play an important role in genesis and development of gastric cancer, which needs our further investigation in detail.
In conclusion, the current study illustrated that downregulation of miR203 and overexpression of PIK3CA were novel potential prognosis predictors of gastric cancer patients. MiR203 as a cancer suppresser can inhibit proliferation and invasion of gastric cancer cells through downregulating PIK3CA. The results of our study will provide new diagnosis and therapeutic targets of gastric cancer. 
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